Zacks: Analysts Set $33.00 Target Price for Phreesia (NYSE:PHR)

Phreesia (NYSE:PHR) has received an average broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus price target of $33.00 for the company, according to Zacks. Zacks has also assigned Phreesia an industry rank of 108 out of 256 based on the ratings given to its competitors.

PHR has been the topic of several analyst reports. Chardan Capital initiated coverage on Phreesia in a research note on Tuesday, July 23rd. They issued a “buy” rating and a $33.00 price objective on the stock. Piper Jaffray Companies initiated coverage on Phreesia in a research note on Monday. They issued an “overweight” rating and a $33.00 price objective on the stock. Wells Fargo & Co initiated coverage on Phreesia in a research note on Monday. They issued an “outperform” rating and a $23.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on Phreesia in a research note on Tuesday. They issued an “overweight” rating and a $33.00 price objective on the stock. Finally, William Blair initiated coverage on Phreesia in a research note on Monday. They issued an “outperform” rating on the stock.

PHR traded down $0.03 on Friday, hitting $28.80. 1,855 shares of the stock traded hands, compared to its average volume of 818,982. Phreesia has a 52 week low of $23.00 and a 52 week high of $29.38.

In other news, major shareholder Ii L.P. Chv sold 335,767 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $18.00, for a total value of $6,043,806.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Scott Perricelli sold 743,388 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $18.00, for a total value of $13,380,984.00. The disclosure for this sale can be found here.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.

Featured Article: How is a buy-side analyst different from a sell-side analyst?

Get a free copy of the Zacks research report on Phreesia (PHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.